Novartis NIBR Global Scholars Program – 2022 call for pre-proposals

Novartis, a global leader in drugs in various therapeutic fields (neurology, immunology, dermatology, cardiology, respiratory diseases, oncology, etc.), is one of the world's highest investing companies in research and development.

In late 2021, the Institut Pasteur decided to participate in the NIBR Global Scholars Program, a funding program for scientific projects run by Novartis, by becoming a partner of the Novartis Institutes for BioMedical Research (NIBR).

With six sites worldwide (in Switzerland, China and the United States) essentially focused on discovery and the fundamental mechanisms of disease, NIBR is the innovation engine of Novartis.

NIBR has introduced the NIBR Global Scholars Program (NGSP) to support scientists from partner institutions leading projects with potential in drug discovery and/or clinical research.

Each project receives up to 1 million USD in funding over three years, along with drug-hunting expertise from dedicated NIBR scientific collaborators.

The program focuses on the following scientific areas of interest*:

- Biologics, Gene Therapy,
- Complex Models,
- Disease Mechanisms,
- Protein & Drug Design,
- Regenerative Medicine,
- Tissue Targeting

*These scientific areas of interest are confidential and should not be passed on to a third party or published on an external website.

More information on this call for proposals

Timetable: April 11, 2022: opening of the call for pre-proposals

If you are interested in this call, please contact:  

Vincent Charpentier (Technology Transfer Department/DARRI): vincent.charpentier@pasteur.fr

Serge Pauillac (Innovation and Entrepreneurship Detection and Funding Department/DARRI): serge.pauillac@pasteur.fr